Adherex Technologies Inc. Announces Phase III Trial With STS in Collaboration With the Children's Oncology Group

RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwire - March 26, 2008) - Adherex Technologies Inc. (TSX: AHX)(AMEX: ADH), a biopharmaceutical company devoted to solving problems for patients with cancer, announced today the activation of a Phase III trial with sodium thiosulfate (STS) to prevent hearing loss in children receiving cisplatin-based chemotherapy in collaboration with the Children's Oncology Group (COG).

Back to news